SAGE Therapeutics

PDUFA Date for Postpartum Depression Drug Delayed Three months
PDUFA Date for Postpartum Depression Drug Delayed Three months
CP Wire
FDA
SAGE Therapeutics
postpartum depression
Zulresso
Flag link:
PDUFA Date for Postpartum Depression Drug Delayed Three months
Zulresso
postpartum depression
SAGE Therapeutics
Flag link:
Sage depression drug to cost between $20K and $35K, if approved
Sage depression drug to cost between $20K and $35K, if approved
Biopharma Dive
SAGE Therapeutics
Zulresso
postpartum depression
FDA
drug pricing
Flag link:
With FDA Panel’s Nod, First Postpartum Depression Drug Nears Approval
With FDA Panel’s Nod, First Postpartum Depression Drug Nears Approval
Xconomy
FDA
advisory panels
SAGE Therapeutics
postpartum depression
brexanolone
Flag link:
FDA reviewers: REMS could allay safety concerns for Sage's brexanolone
FDA reviewers: REMS could allay safety concerns for Sage's brexanolone
BioCentury
FDA
SAGE Therapeutics
postpartum depression
SAGE-547
brexanolone
REMS
Flag link:
Sage Therapeutics’ chief scientist on discovering drugs and taking risks
Sage Therapeutics’ chief scientist on discovering drugs and taking risks
Drug Delivery Business News
SAGE Therapeutics
drug discovery
drug development
Flag link:
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
Endpoints
SAGE Therapeutics
SAGE-217
Asia
Shionogi
depression
Flag link:
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
CP Wire
SAGE Therapeutics
FDA
breakthrough status
SAGE-217
major depressive disorder
postpartum depression
Flag link:
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
SAGE Therapeutics
SAGE-217
major depressive disorder
postpartum depression
Flag link:
Sage Therapeutics wins priority review for intravenous postpartum depression drug
Sage Therapeutics wins priority review for intravenous postpartum depression drug
Drug Delivery Business News
SAGE Therapeutics
FDA
brexanolone
postpartum depression
Flag link:
Sage Postpartum Depression Drug Heads to FDA Review
Sage Postpartum Depression Drug Heads to FDA Review
Xconomy
SAGE Therapeutics
FDA
brexanolone
postpartum depression
Flag link:
3 Small Biotechs That Big Drugmakers Are Probably Drooling Over
3 Small Biotechs That Big Drugmakers Are Probably Drooling Over
Motley Fool
biotech
Bluebird Bio
Madrigal Pharmaceuticals
SAGE Therapeutics
Flag link:
5 Biotech Buyout Candidates for 2018
5 Biotech Buyout Candidates for 2018
Yahoo/Motley Fool
biotech
M&A
Biogen
Biomarin
Bluebird Bio
Geron
SAGE Therapeutics
Flag link:
Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test
Sage Shares Soar Again As Depression Drug Hits Mark in Phase 2 Test
Xconomy
SAGE Therapeutics
major depressive disorder
SAGE-217
Flag link:
3 Biotech Stocks That Soared This Week
3 Biotech Stocks That Soared This Week
Motley Fool
biotech
Nektar
earnings
SAGE Therapeutics
brexanolone
postpartum depression
Valeant Pharmaceuticals
Flag link:
Sage Bounces Back, Eyes FDA Filing for Postpartum Drug
Sage Bounces Back, Eyes FDA Filing for Postpartum Drug
Xconomy
SAGE Therapeutics
postpartum depression
brexanolone
FDA
clinical trials
Flag link:
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter
Stat
biotech
Axovant Sciences
intepirdine
SAGE Therapeutics
brexanolone
AbbVie
risankizumab
Global Blood Therapeutics
GBT-440
DBV Technologies
Viaskin Peanut
Cytokinetics
Amicus Therapeutics
ATB200
Spark Therapeutics
Bluebird Bio
Revance Therapeutics
RT002
Flag link:
Sage’s epilepsy drug fails to do better than placebo in key clinical trial
Sage’s epilepsy drug fails to do better than placebo in key clinical trial
Stat
SAGE Therapeutics
epilepsy
clinical trials
brexanolone
Flag link:
Sage Therapeutics reports 4Q loss
Sage Therapeutics reports 4Q loss
Yahoo/AP
SAGE Therapeutics
earnings
Flag link:
Sage Therapeutics Leads Biotech Movers on False Takeout Rumors
Sage Therapeutics Leads Biotech Movers on False Takeout Rumors
TheStreet.com
SAGE Therapeutics
M&A
Flag link:

Pages